We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Reviewing PFE’s five-year history, the stock has experienced a balanced 50-50 distribution of positive and negative returns ...

Pfizer’s stock, listed on the New York Stock Exchange (NYSE), remains stable despite the danuglipron announcement. Meanwhile, Viking’s stock, listed on the Nasdaq exchange, jumped by 21% at market ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Pfizer (NYSE:PFE) recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its ...

New York is part of a $335 million multistate settlement with a spin-off company of the pharmaceutical giant Pfizer for its role in the opioid epidemic over the last twenty years. The leaders of ...

Shares in 5,432 companies trade every day starting at 9:30 on the New York Stock Exchange or Nasdaq ... week’s respective drops of 17% and 18%. Pfizer fell another 1% Monday, for a total ...

NEW YORK, April 14, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1 ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.